Approved SAPPHIRE trial is a prospective, multicenter, open-label clinical trial with 1-year follow up, evaluating safety and effectiveness of VisiPlate® aqueous shunt in glaucoma patients.
VisiPlate® shunt is uniquely designed: novel metamaterial, thinner than a human hair, aiming for longevity, comfort, and aesthetics.
The multiple, redundant microchannels provide sustained aqueous flow while minimizing the risk of blockage and re-intervention.
REDWOOD CITY, Calif., Oct. 14, 2025 /PRNewswire/ — Avisi Technologies, Inc., an ophthalmic medical device company advancing novel, sight-saving technologies, announces that the US Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) submission for Avisi’s glaucoma treatment device VisiPlate®.